Evidence map›Paper›PMID 30794069›Full record

ReviewTissue engineering. Part A2019

Emerging Technologies for Tissue Engineering: From Gene Editing to Personalized Medicine.

James P K Armstrong, Molly M Stevens

Abstract readReview
In one paragraph

Review in Tissue engineering. Part A, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Recent advances in artificial intelligent strategies for tissue engineering and regenerative medicine.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Theranostic biomaterials for tissue engineering.Current opinion in biomedical engineering · 2021
    Article
  11. Emerging strategies in reprogramming and enhancing the fate of mesenchymal stem cells for bone and cartilage tissue engineering.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  12. A blueprint for translational regenerative medicine.Science translational medicine · 2020
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

James P K ArmstrongDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, United Kingdom.
Molly M StevensDepartment of Materials, Department of Bioengineering, and Institute of Biomedical Engineering, Imperial College London, London, United Kingdom.

Funding

European Research Council 616417Medical Research Council MR/R015651/1Medical Research Council MR/S00551X/1Wellcome Trust 098411
6 · The paper itself

Abstract

impact statementHistory has shown us how tissue engineering can be advanced by embracing technological innovation. In this perspective, we highlight some of the most promising emerging technologies and discuss how they can be integrated into existing tissue engineering protocols. The proposed technologies offer the opportunity to reshape how we currently design, engineer, and characterize tissue grafts for improved

Indexed as

Gene EditingPrecision MedicineTissue EngineeringHumanscharacterizationgene editingpersonalized medicinetechnologiestissue engineering

Identifiers

PMID30794069
PMCPMC6606435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.